Mississippi Oncology Society

01/29/2026

https://www.facebook.com/share/p/1AwkNPQ9Mu/?mibextid=wwXIfr
This was one of over 50 recommendations which came from the Mississippi Comprehensive Cancer Control Coalition Task Force that MOS helped administer. Proud to see patient driven issues being addressed by our Legislators. Special thanks to Rep Sam Creekmore and Rep Kevin Felsher for their commitment to seeing this bill become law during this session.

The Mississippi House of Representatives unanimously passed legislation Wednesday that would require state-regulated health insurance plans to cover biomarker

01/27/2026

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel

01/20/2026

This guidance provides recommendations to sponsors about using minimal residual disease (MRD) and complete response (CR) in multiple myeloma.

01/16/2026

https://www.msmaonline.com/_Core/Events/Event_Display.aspx?EventKey=WCD2026&WebsiteKey=cb99ab48-42ff-40f4-a7b8-e671c03b2a19
MOS physician members and Fellows are encouraged to attend. Registration link is above.

01/10/2026

https://www.facebook.com/share/1AXCaJkvuU/?mibextid=wwXIfr

🎉 We’re proud to share that CCRI is featured in the January 2026 AACI Update Newsletter, published by the Association of American Cancer Institutes!
The recognition highlights impactful research led by Dr. Keli Xu, showcasing the important cancer research happening at the Cancer Center and Research Institute at UMMC and its national reach.
Congratulations to Dr. Xu and the research team at CCRI — your dedication and innovation continue to elevate our mission and bring national attention to the life-saving work happening right here in Mississippi! https://www.aaci-cancer.org/aaci-update-january-2026

01/09/2026

https://www.facebook.com/share/17BRZRPc5i/?mibextid=wwXIfr

The Cancer Center and Research Institute at the University of Mississippi Medical Center is now an Optum Center of Excellence for Cellular Immunotherapy and Gene Therapy, an achievement that recognizes UMMC for meeting rigorous standards in delivering advanced CAR T-cell therapy and exceptional pati...

12/25/2025

12/18/2025

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients

12/17/2025

On December 17, 2025, the Food and Drug Administration (FDA) approved rucaparib (Rubraca, pharmaand GmbH).

12/15/2025

On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab f

12/14/2025

On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer.

12/14/2025

https://bluetoad.com/publication/?i=858151&p=1&view=issueViewer
December Edition of Insights from MOS

December 2025 Insights newsletters are published by Bay Media, Inc. as part of Strategies Magazine . To advertise contact adsales@strategiesoncology.com | 410 -647-8402 Mississippi Comprehensive Cancer Care Committee November Meeting Angela Ladner, executive director of MOS, shared the minutes from....